Synonyms: APX-115 | APX115 | EWHA-18278 (free base)
Compound class:
Synthetic organic
Comment: Isuzinaxib (APX-115) is a first-in-class pan-NADPH oxidase (NOX) inhibitor [1]. We show the chemical structure for the free base, but it is generally delivered as the hydrochloride salt. Isuzinaxib was designed to reduce cellular oxidative stress and tissue injury caused by imbalanced reactive oxygen species (ROS) production in pathological condtions. NADPH oxidases (NOX1-5, DUOX1 and DUOX2) are the major sources of ROS. The effects of pan-NOX inhibition by isuzinaxib can be compared with the effects of the dual NOX1/NOX4 inhibitor setanaxib (GKT137831) [2].
COVID-19: ROS production in response to virus infection are known activators that promote apoptosis, lung injury, and inflammation. Isuzinaxib is being evaluated as a clinical agent that may reduce ROS-induced tissue damage in SARS-CoV-2 infected patients. |
|
Classification ![]() |
|
Compound class | Synthetic organic |
International Nonproprietary Names ![]() |
|
INN number | INN |
11535 | isuzinaxib |
Synonyms ![]() |
APX-115 | APX115 | EWHA-18278 (free base) |
Database Links ![]() |
|
CAS Registry No. | 1270084-92-8 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL4650894 |
GtoPdb PubChem SID | 464244126 |
PubChem CID | 51036475 |
Search Google for chemical match using the InChIKey | GIWZEELPLKPYBA-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | GIWZEELPLKPYBA |
Search PubMed clinical trials | isuzinaxib |
Search PubMed titles | isuzinaxib |
Search PubMed titles/abstracts | isuzinaxib |
UniChem Compound Search for chemical match using the InChIKey | GIWZEELPLKPYBA-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | GIWZEELPLKPYBA-UHFFFAOYSA-N |